

Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029

Market Report | 2024-03-15 | 351 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The monoclonal antibody therapeutics market is projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, at a CAGR of 14.5% during the forecast period.

The driving factors of the monoclonal antibody therapeutics market include increased prevalence of chronic diseases, advancements in biotechnology, and growing demand for targeted therapies. Examples include drugs like Rituxan (rituximab) for lymphoma, Humira (adalimumab) for autoimmune disorders, and Keytruda (pembrolizumab) for cancer immunotherapy, driving market growth through their effectiveness and broad applications.

"The In-Vitro segment accounted for the largest share by production method in 2023."

Based on production method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In 2023, in-vitro segment dominated the monoclonal antibody therapeutics market. Driving factors of the in-vitro production method monoclonal antibody therapeutics market include scalability, cost-effectiveness, reduced batch-to-batch variability, and regulatory compliance, meeting demand for reliable and consistent biopharmaceutical production.

"The human segment accounted for the largest share by source in 2023."

Based on source, the monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human source segment dominated market and humanized segment is likely to grow at significant CAGR during the forecast period. The driving factors of the human source monoclonal antibody therapeutics market include reduced immunogenicity, enhanced efficacy, and improved safety profiles compared to non-human sources. Additionally, advancements in humanization techniques and increased understanding of human immune responses contribute to the growth of this market,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

catering to diverse therapeutic needs.

"The autoimmune & inflammatory disease segment accounted for the largest share by therapy area in 2023."

The monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, Oncology, Hematology, ophthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases dominated the monoclonal antibody therapeutics market. Cancer segment is anticipated to grow at significant CAGR during the forecast period of 2024-2029. The high growth cancer monoclonal antibody therapeutics is propelled by increasing incidences of cancer globally, coupled with growing acceptance of targeted therapies. Continuous research and development efforts, along with advancements in biotechnology, contribute to the robust growth trajectory of this segment.

"The Europe is growing at the highest CAGR in the monoclonal antibody therapeutics market during the forecast period of 2024-2029."

North America dominates the monoclonal antibody therapeutics market. Europe, is likely to grow at highest CAGR owing to various factors such as favorable regulatory frameworks, robust healthcare infrastructure, increasing investment in research and development, and rising prevalence of chronic diseases. These elements collectively foster a conducive environment for market expansion and innovation.

The primary interviews conducted for this report can be categorized as follows:

-By Respondent: Supply Side- 70% and Demand Side 30%

-By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives- 25%

-By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

List of Companies Profiled in the Report:

-F. Hoffmann-La Roche Ltd (Switzerland)

-Abbvie Inc. (US)

-Johnson & Johnson Services, Inc. (US)

-Merck & Co., Inc. (US)

-Bristol Myers Squibb Company (US)

-AstraZeneca (UK)

-Sanofi (France)

-Novartis AG (Switzerland)

-Amgen Inc. (US)

-Takeda Pharmaceutical Company Limited (Japan)

-GSK plc. (UK)

-Eli Lilly and Company (US)

-Regeneron Pharmaceuticals Inc. (US)

-Biogen (US)

-UCB S.A. (Belgium)

-Boehringer Ingelheim International GmbH (Germany)

-Y-mAbs Therapeutics Inc. (US)

-Teva Pharmaceutical Industries Ltd. (Israel),

-Merck KGaA (Germany)

-Kyowa Kirin Co. Ltd. (Japan)

-Swedish Orphan Biovitrum AB (Sweden)

-United Therapeutics Corporation (US)

-Theratechnologies Inc. (Canada)

-Incyte (US)

-Sun Pharmaceutical Industries Ltd. (India)

Research Coverage:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This research report categorizes the monoclonal antibody therapeutics market by production method (in-vitro and in-vivo), source (human, humanized, chimeric and other sources), therapy area (autoimmune & inflammatory disorders, Oncology, Hematology, ophthalmology and other therapy area), route of administration (intravenous, subcutaneous and other route of administration), end user (hospitals, long-term care facilities, and other end user) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and trends influencing the growth of the monoclonal antibody therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product/service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the monoclonal antibody therapeutics market. Competitive analysis of top players and upcoming startups in the monoclonal antibody therapeutics market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall monoclonal antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Advancements in biotechnology and genetic engineering, Increasing demand for personalized medicine, Growing product pipeline of innovative mAb therapeutics) restraints (Stringent regulatory approval process and High cost of mAb treatments), opportunities (Innovative therapeutic indications, Rising technological advancements in antibody engineering), and challenges (Rising production costs for mAbs) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the monoclonal antibody therapeutics market
- Clinical Trials: Detail Analysis on the products under clinical trials phase III and phase II&III.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the monoclonal antibody therapeutics market
- Competitive Assessment: are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), among others in the market.

Table of Contents:

1□INTRODUCTION□	29
1.1□STUDY OBJECTIVES□	29
1.2□MARKET DEFINITION□	29
1.2.1□INCLUSIONS & EXCLUSIONS□	29
1.3□MARKET SCOPE□	30
1.3.1□MARKETS COVERED□	30
1.3.2□YEARS CONSIDERED□	31
1.3.3□CURRENCY CONSIDERED□	31
1.4□RESEARCH LIMITATIONS□	31
1.5□STAKEHOLDERS□	32
1.6□RECESSION IMPACT□	32
2□RESEARCH METHODOLOGY□	33
2.1□RESEARCH DATA□	33
FIGURE 1□RESEARCH DESIGN□	33
2.1.1□SECONDARY DATA□	34
2.1.2□PRIMARY DATA□	35

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 2	MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES	35
2.2	MARKET SIZE ESTIMATION	36
FIGURE 3	MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023	36
FIGURE 4	MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023	37
FIGURE 5	MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023	38
FIGURE 6	ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023	38
2.2.1	INSIGHTS FROM PRIMARIES	40
FIGURE 7	MARKET VALIDATION FROM PRIMARY EXPERTS	40
2.2.2	SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER)	40
FIGURE 8	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	40
2.3	GROWTH RATE ASSUMPTIONS	41
FIGURE 9	MONOCLONAL ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS, 2024-2029	42
FIGURE 10	MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES	42
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	43
FIGURE 11	DATA TRIANGULATION METHODOLOGY	43
2.5	STUDY ASSUMPTIONS	44
2.6	RISK ANALYSIS	44
2.7	RECESSION IMPACT ANALYSIS	45
3	EXECUTIVE SUMMARY	46
FIGURE 12	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION)	46
FIGURE 13	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)	47
FIGURE 14	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION)	47
FIGURE 15	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)	48
FIGURE 16	GEOGRAPHICAL SNAPSHOT OF MONOCLONAL ANTIBODY THERAPEUTICS MARKET	49
4	PREMIUM INSIGHTS	50
4.1	MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW	50
FIGURE 17	ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD	50
4.2	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (2023)	51
FIGURE 18	IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023	51
4.3	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)	51
FIGURE 19	HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD	51
4.4	MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	52
FIGURE 20	GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	52
5	MARKET OVERVIEW	53
5.1	INTRODUCTION	53
5.2	MARKET DYNAMICS	53
FIGURE 21	MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	53
5.2.1	DRIVERS	54
5.2.1.1	Advancements in biotechnology and genetic engineering	54
5.2.1.2	Increasing demand for personalized medicine	55
5.2.1.3	Growing product pipeline of mAb therapeutics	55
FIGURE 22	NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012-2023)	56
5.2.2	RESTRAINTS	56
5.2.2.1	Stringent regulatory approval process	56
5.2.2.2	High cost of mAb treatments	57

5.2.3 OPPORTUNITIES 57

5.2.3.1 Innovative therapeutic indications 57

5.2.3.2 Rising technological advancements in antibody engineering 58

?

5.2.4 CHALLENGES 59

5.2.4.1 Rising development & production costs 59

5.3 PORTER'S FIVE FORCES ANALYSIS 59

TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS 59

5.3.1 THREAT OF NEW ENTRANTS 59

5.3.2 THREAT OF SUBSTITUTES 60

5.3.3 BARGAINING POWER OF SUPPLIERS 60

5.3.4 BARGAINING POWER OF BUYERS 60

5.3.5 INTENSITY OF COMPETITIVE RIVALRY 60

5.4 TECHNOLOGY ANALYSIS 60

5.4.1 CONVENTIONAL PRODUCTION OF MABS 61

5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS 61

TABLE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: TECHNOLOGY COMPARISON 62

5.5 VALUE CHAIN ANALYSIS 63

FIGURE 23 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN 63

5.6 PATENT ANALYSIS 64

5.6.1 METHODOLOGY 64

5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014-2023 64

TABLE 3 PATENTS FILED, 2014-2023 64

5.6.3 INNOVATION AND PATENT APPLICATIONS 65

FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014-2023 65

5.6.4 TOP APPLICANTS 65

FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2023 65

FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014-2023 66

TABLE 4 TOP 10 PATENT OWNERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2013-2023 66

TABLE 5 PATENTS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2023-2024 67

5.7 KEY CONFERENCES & EVENTS 68

TABLE 6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024-2025) 68

5.8 INVESTMENT AND FUNDING SCENARIO 69

5.9 PIPELINE ANALYSIS 69

TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE 70

5.10 SUPPLY CHAIN ANALYSIS 77

FIGURE 27 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 78

5.11 ECOSYSTEM ANALYSIS 78

FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM 78

5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 78

TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 79

5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS 79

TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS 79

5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS 80

TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES 80

5.12 REGULATORY LANDSCAPE 80

5.12.1 REGULATORY ANALYSIS 80

5.12.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
TABLE 11	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
TABLE 12	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
TABLE 13	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	82
TABLE 14	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	82
5.13	PRICING ANALYSIS	83
5.13.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS	83
TABLE 15	AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US	83
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	83
FIGURE 29	TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH	84
5.15	KEY STAKEHOLDERS AND BUYING CRITERIA	85
5.15.1	KEY STAKEHOLDERS ON BUYING PROCESS	85
FIGURE 30	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS	85
TABLE 16	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS	85
5.15.2	BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS	86
FIGURE 31	KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES	86
TABLE 17	KEY BUYING CRITERIA FOR TOP TWO END USERS	86
6	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD	88
6.1	INTRODUCTION	89
TABLE 18	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)	89
6.2	IN-VITRO PRODUCTION	89
6.2.1	HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET	89
TABLE 19	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)	90
TABLE 20	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	90
TABLE 21	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	91
TABLE 22	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	91
TABLE 23	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	92
TABLE 24	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)	92
TABLE 25	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	92
6.3	IN-VIVO PRODUCTION	93
6.3.1	MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH	93
TABLE 26	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)	93
TABLE 27	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	94
TABLE 28	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	94
TABLE 29	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	95
TABLE 30	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)	95
TABLE 31	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022-2029	

(USD MILLION)96

TABLE 32GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)96

7MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION97

7.1INTRODUCTION98

TABLE 33MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)98

7.2INTRAVENOUS ROUTE OF ADMINISTRATION98

7.2.1DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET98

TABLE 34MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)99

TABLE 35NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)99

TABLE 36EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)100

TABLE 37ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)100

TABLE 38LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)101

TABLE 39MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)101

TABLE 40GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)101

7.3SUBCUTANEOUS ROUTE OF ADMINISTRATION102

7.3.1ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET102

TABLE 41MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)103

TABLE 42NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)103

TABLE 43EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)104

TABLE 44ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)104

TABLE 45LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)105

TABLE 46MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 USD MILLION)105

TABLE 47GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)105

7.4OTHER ROUTES OF ADMINISTRATION106

TABLE 48MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)106

TABLE 49NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)107

TABLE 50EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)107

TABLE 51ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 52	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)	108
TABLE 53	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)	109
TABLE 54	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)	109
8	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE	110
8.1	INTRODUCTION	111
TABLE 55	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)	111
8.2	HUMAN SOURCE	111
8.2.1	REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET	111
TABLE 56	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022-2029 (USD MILLION)	112
TABLE 57	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	112
TABLE 58	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	113
TABLE 59	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	113
TABLE 60	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	114
TABLE 61	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022-2029 (USD MILLION)	114
TABLE 62	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	114
8.3	HUMANIZED SOURCE	115
8.3.1	ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET	115
TABLE 63	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022-2029 (USD MILLION)	115
TABLE 64	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	116
TABLE 65	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	116
TABLE 66	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	117
TABLE 67	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	117
TABLE 68	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022-2029 (USD MILLION)	118
TABLE 69	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	118
8.4	CHIMERIC SOURCE	118
8.4.1	UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET	118
TABLE 70	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022-2029 (USD MILLION)	119
TABLE 71	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	119
TABLE 72	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)	120
TABLE 73	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION)120

TABLE 741LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)121

TABLE 752MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022-2029 (USD MILLION)121

TABLE 763GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)121

8.54OTHER SOURCES122

TABLE 775MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)122

TABLE 786NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)123

TABLE 797EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)123

TABLE 808ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)124

TABLE 819LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)124

TABLE 820MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)125

TABLE 831GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)125

92MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA126

9.13INTRODUCTION127

TABLE 844MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)127

9.25INFLAMMATORY & AUTOIMMUNE DISORDERS127

9.2.16RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET127

TABLE 857MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022-2029 (USD MILLION)128

TABLE 868NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)128

TABLE 879EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)129

TABLE 880ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)129

TABLE 891LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)130

TABLE 902MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022-2029 (USD MILLION)130

TABLE 913GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)130

9.34ONCOLOGY131

9.3.15GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET131

TABLE 926MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)132

TABLE 937NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)132

TABLE 948EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)133

TABLE 959ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 133

TABLE 96 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) 134

TABLE 97 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION) 134

TABLE 98 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) 134

?

9.4 HEMATOLOGY 135

9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH 135

TABLE 99 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION) 135

TABLE 100 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 101 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 102 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 137

TABLE 103 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 137

TABLE 104 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION) 138

TABLE 105 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 138

9.5 OPHTHALMOLOGY 138

9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND 138

TABLE 106 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2029 (USD MILLION) 139

TABLE 107 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 139

TABLE 108 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 140

TABLE 109 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 140

TABLE 110 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 141

TABLE 111 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2029 (USD MILLION) 141

TABLE 112 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 141

9.6 OTHER THERAPY AREAS 142

TABLE 113 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2029 (USD MILLION) 143

TABLE 114 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 143

TABLE 115 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 144

TABLE 116 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 144

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 117	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)	145
TABLE 118	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2029 (USD MILLION)	145
TABLE 119	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)	145
10	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER	146
10.1	INTRODUCTION	147
TABLE 120	MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)	147
10.2	HOSPITALS	147
10.2.1	AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET	147
TABLE 121	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)	148
TABLE 122	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)	148
TABLE 123	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)	149
TABLE 124	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)	149
TABLE 125	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)	150
TABLE 126	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)	150
TABLE 127	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)	150
10.3	LONG-TERM CARE FACILITIES	151
10.3.1	SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET	151
TABLE 128	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)	151
TABLE 129	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	152
TABLE 130	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	152
TABLE 131	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	153
TABLE 132	LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	153
TABLE 133	MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)	154
TABLE 134	GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	154
10.4	OTHER END USERS	155
TABLE 135	MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)	155
TABLE 136	NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)	155
TABLE 137	EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)	156
TABLE 138	ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION)156

TABLE 139LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029

(USD MILLION)157

TABLE 140MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)157

TABLE 141GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)157

11MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION158

11.1INTRODUCTION159

TABLE 142MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION)159

11.2NORTH AMERICA159

FIGURE 32NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT160

TABLE 143NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)161

TABLE 144NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)161

TABLE 145NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)162

TABLE 146NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)162

TABLE 147NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)163

TABLE 148NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)163

11.2.1NORTH AMERICA: RECESSION IMPACT164

11.2.2US164

11.2.2.1Rising regulatory approvals for product commercialization to propel market164

TABLE 149PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA165

TABLE 150US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)165

TABLE 151US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)166

TABLE 152US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)166

TABLE 153US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)167

TABLE 154US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)167

11.2.3CANADA167

11.2.3.1Rising investments in antibody research to support market growth167

TABLE 155CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)168

TABLE 156CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)168

TABLE 157CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)169

TABLE 158CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)169

TABLE 159CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)170

11.3EUROPE170

FIGURE 33EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT171

TABLE 160EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)172

TABLE 161EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)172

TABLE 162EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)173

TABLE 163EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)173

TABLE 164EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)174

TABLE 165EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)174

11.3.1EUROPE: RECESSION IMPACT174

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3.2 GERMANY 175

11.3.2.1 Rising number of clinical trials for mAb therapeutics to drive market 175

TABLE 166 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION) 175

TABLE 167 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 175

TABLE 168 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 176

TABLE 169 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION) 176

TABLE 170 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 177

11.3.3 UK 177

11.3.3.1 Increasing R&D initiatives by pharmaceutical & biotechnology companies to support market growth 177

TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 177

TABLE 172 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION) 178

TABLE 173 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 178

TABLE 174 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 178

TABLE 175 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION) 179

TABLE 176 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 179

11.3.4 FRANCE 180

11.3.4.1 Favorable reimbursement policies for therapeutic treatments to propel market 180

TABLE 177 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION) 180

TABLE 178 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 180

TABLE 179 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 181

TABLE 180 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION) 181

TABLE 181 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 182

11.3.5 ITALY 182

11.3.5.1 Growth in life sciences industry to boost demand 182

TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION) 182

TABLE 183 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 183

TABLE 184 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 183

TABLE 185 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION) 184

TABLE 186 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 184

11.3.6 SPAIN 185

11.3.6.1 Growing focus on research for biomaterial development to drive market 185

TABLE 187 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION) 185

TABLE 188 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 185

TABLE 189 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 186

TABLE 190 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION) 186

TABLE 191 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 187

11.3.7 TURKEY 187

11.3.7.1 Rising investments in R&D for healthcare infrastructure to support market growth 187

TABLE 192 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION) 188

TABLE 193 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 188

TABLE 194 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 188

TABLE 195 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION) 189

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 196TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)189

11.3.8REST OF EUROPE190

TABLE 197REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)190

TABLE 198REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)190

TABLE 199REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)191

TABLE 200REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)191

TABLE 201REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)192

Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029

Market Report | 2024-03-15 | 351 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature